Drug	O
release	O
studies	B:C2603343
from	O
lipid	O
nanoparticles	O
in	O
physiological	O
media	O
by	O
a	O
new	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
method	O
.	O

Drug	O
release	O
studies	O
from	O
lipid	B:C0023779
nanoparticles	O
in	O
physiological	O
media	O
by	O
a	O
new	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
method	O
.	O

Drug	O
release	O
studies	O
from	O
lipid	O
nanoparticles	O
in	O
physiological	O
media	B:C0010454
by	O
a	O
new	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
method	O
.	O

Drug	O
release	O
studies	O
from	O
lipid	O
nanoparticles	O
in	O
physiological	O
media	O
by	O
a	O
new	O
differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
method	O
.	O

Drug	O
release	O
studies	O
from	O
lipid	O
nanoparticles	O
in	O
physiological	O
media	O
by	O
a	O
new	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
method	B:C0025663
.	O

Lipid	B:C0023779
nanoparticles	O
are	O
an	O
interesting	O
parenteral	O
delivery	O
system	O
for	O
poorly	O
water	O
-	I:C1254351
soluble	I:C1254351
drugs	I:C1254351
.	O

Lipid	O
nanoparticles	O
are	O
an	O
interesting	O
parenteral	O
delivery	O
system	O
for	O
poorly	O
water	B:C1254351
-	I:C1254351
soluble	I:C1254351
drugs	I:C1254351
.	O

In	O
order	O
to	O
approach	O
physiological	O
conditions	O
when	O
conducting	O
release	O
studies	B:C2603343
from	O
such	O
systems	O
the	O
release	O
media	O
should	O
preferentially	O
contain	O
lipophilic	O
acceptor	O
compartments	O
such	O
as	O
lipoproteins	O
or	O
other	O
colloidal	O
lipophilic	O
components	O
.	O

In	O
order	O
to	O
approach	O
physiological	O
conditions	O
when	O
conducting	O
release	O
studies	O
from	O
such	O
systems	O
the	O
release	O
media	B:C0010454
should	O
preferentially	O
contain	O
lipophilic	O
acceptor	O
compartments	O
such	O
as	O
lipoproteins	O
or	O
other	O
colloidal	O
lipophilic	O
components	O
.	O

In	O
order	O
to	O
approach	O
physiological	O
conditions	O
when	O
conducting	O
release	O
studies	O
from	O
such	O
systems	O
the	O
release	O
media	O
should	O
preferentially	O
contain	O
lipophilic	O
acceptor	O
compartments	O
such	O
as	O
lipoproteins	B:C0023820
or	O
other	O
colloidal	O
lipophilic	O
components	O
.	O

In	O
order	O
to	O
approach	O
physiological	O
conditions	O
when	O
conducting	O
release	O
studies	O
from	O
such	O
systems	O
the	O
release	O
media	O
should	O
preferentially	O
contain	O
lipophilic	O
acceptor	O
compartments	O
such	O
as	O
lipoproteins	O
or	O
other	O
colloidal	B:C0009361
lipophilic	O
components	O
.	O

In	O
practice	O
,	O
drug	O
release	O
studies	B:C2603343
under	O
such	O
close	O
to	O
physiological	O
conditions	O
may	O
be	O
complicated	O
by	O
the	O
small	O
size	O
of	O
lipid	O
nanoparticles	O
,	O
which	O
is	O
in	O
the	O
same	O
range	O
as	O
that	O
of	O
the	O
potential	O
acceptor	O
particles	I:C0597177
.	O

In	O
practice	O
,	O
drug	O
release	O
studies	O
under	O
such	O
close	O
to	O
physiological	O
conditions	O
may	O
be	O
complicated	O
by	O
the	O
small	O
size	O
of	O
lipid	B:C0023779
nanoparticles	O
,	O
which	O
is	O
in	O
the	O
same	O
range	O
as	O
that	O
of	O
the	O
potential	O
acceptor	O
particles	I:C0597177
.	O

In	O
practice	O
,	O
drug	O
release	O
studies	O
under	O
such	O
close	O
to	O
physiological	O
conditions	O
may	O
be	O
complicated	O
by	O
the	O
small	O
size	O
of	O
lipid	O
nanoparticles	O
,	O
which	O
is	O
in	O
the	O
same	O
range	O
as	O
that	O
of	O
the	O
potential	O
acceptor	B:C0597177
particles	I:C0597177
.	O

This	O
study	B:C2603343
describes	O
a	O
novel	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
method	O
for	O
drug	O
release	O
measurements	O
which	O
works	O
without	O
separation	O
of	O
donor	O
and	O
acceptor	O
particles	I:C0597177
.	O

This	O
study	O
describes	O
a	O
novel	O
differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
method	O
for	O
drug	O
release	O
measurements	O
which	O
works	O
without	O
separation	O
of	O
donor	O
and	O
acceptor	O
particles	I:C0597177
.	O

This	O
study	O
describes	O
a	O
novel	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
)	O
method	O
for	O
drug	O
release	O
measurements	O
which	O
works	O
without	O
separation	O
of	O
donor	O
and	O
acceptor	O
particles	I:C0597177
.	O

This	O
study	O
describes	O
a	O
novel	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
method	B:C0025663
for	O
drug	O
release	O
measurements	O
which	O
works	O
without	O
separation	O
of	O
donor	O
and	O
acceptor	O
particles	I:C0597177
.	O

This	O
study	O
describes	O
a	O
novel	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
method	O
for	O
drug	O
release	O
measurements	O
which	O
works	O
without	O
separation	O
of	O
donor	B:C0597177
and	O
acceptor	O
particles	I:C0597177
.	O

This	O
study	O
describes	O
a	O
novel	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
(	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
)	O
method	O
for	O
drug	O
release	O
measurements	O
which	O
works	O
without	O
separation	O
of	O
donor	O
and	O
acceptor	B:C0597177
particles	I:C0597177
.	O

The	O
technique	O
is	O
based	O
on	O
measuring	O
the	O
crystallization	O
temperature	O
of	O
trimyristin	B:C0077214
nanoparticles	O
by	O
differential	O
scanning	I:C0006780
calorimetry	I:C0006780
.	O

The	O
technique	O
is	O
based	O
on	O
measuring	O
the	O
crystallization	O
temperature	O
of	O
trimyristin	O
nanoparticles	O
by	O
differential	B:C0006780
scanning	I:C0006780
calorimetry	I:C0006780
.	O

Liquid	O
trimyristin	B:C0077214
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	B:C0033228
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	B:C0076275
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	B:C0078373
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	B:C0056077
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	B:C0010454
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	B:C0039005
serum	O
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	B:C0229671
and	O
porcine	O
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	B:C0039005
blood	O
.	O

Liquid	O
trimyristin	O
nanoparticles	O
loaded	O
with	O
fenofibrate	O
,	O
orlistat	O
,	O
tocopherol	O
acetate	I:C0078373
and	O
ubidecarenone	O
were	O
studied	O
in	O
three	O
different	O
release	O
media	O
with	O
increasing	O
complexity	O
and	O
comparability	O
to	O
physiological	O
conditions	O
:	O
a	O
rapeseed	O
oil	O
nanoemulsion	O
,	O
porcine	O
serum	O
and	O
porcine	O
blood	B:C0005767
.	O

Using	O
the	O
new	B:C0025663
method	I:C0025663
,	O
a	O
correlation	O
between	O
release	O
behavior	O
and	O
drug	O
lipophilicity	O
was	O
observed	O
:	O
the	O
higher	O
the	O
logP	O
value	O
of	O
the	O
drug	O
,	O
the	O
slower	O
the	O
release	O
.	O

Using	O
the	O
new	O
method	I:C0025663
,	O
a	O
correlation	O
between	O
release	O
behavior	O
and	O
drug	B:C1254351
lipophilicity	O
was	O
observed	O
:	O
the	O
higher	O
the	O
logP	O
value	O
of	O
the	O
drug	O
,	O
the	O
slower	O
the	O
release	O
.	O

Using	O
the	O
new	O
method	I:C0025663
,	O
a	O
correlation	O
between	O
release	O
behavior	O
and	O
drug	O
lipophilicity	O
was	O
observed	O
:	O
the	O
higher	O
the	O
logP	O
value	O
of	O
the	O
drug	B:C1254351
,	O
the	O
slower	O
the	O
release	O
.	O

The	O
extent	O
of	O
drug	O
release	O
was	O
influenced	O
by	O
partition	O
equilibrium	O
as	O
indicated	O
by	O
increased	O
drug	O
release	O
in	O
the	O
rapeseed	O
oil	O
nanoemulsion	O
compared	O
to	O
porcine	B:C0039005
serum	O
and	O
blood	O
.	O

The	O
extent	O
of	O
drug	O
release	O
was	O
influenced	O
by	O
partition	O
equilibrium	O
as	O
indicated	O
by	O
increased	O
drug	O
release	O
in	O
the	O
rapeseed	O
oil	O
nanoemulsion	O
compared	O
to	O
porcine	O
serum	B:C0229671
and	O
blood	O
.	O

The	O
extent	O
of	O
drug	O
release	O
was	O
influenced	O
by	O
partition	O
equilibrium	O
as	O
indicated	O
by	O
increased	O
drug	O
release	O
in	O
the	O
rapeseed	O
oil	O
nanoemulsion	O
compared	O
to	O
porcine	O
serum	O
and	O
blood	B:C0005767
.	O

